How This German Biotech's $6.4M Seed Round Aims to Redefine Heart Disease Treatment

Jan de Vries · 2026-08-28

In a significant move for European biotech, a Heidelberg-based startup called Revier Therapeutics has just launched with a fresh $6.4 million seed round to tackle some of the most persistent cardiometabolic diseases. That's right, they've converted their €6 million into roughly $6.4 million to fund their ambitious science. The funding round was spearheaded by the KHAN Technology Transfer Fund II, with key contributions from High-Tech Gründerfonds (HTGF), VORNvc, and private investors through Revier Invest Heidelberg. This coalition of backers signals strong confidence in the company's novel approach. ### The Unmet Need in Cardiovascular Care Let's talk about the problem they're solving. Despite all the advances in medicine, millions of patients are still stuck with limited options. We're talking about conditions like heart failure with preserved ejection fraction (HFpEF) and atherosclerotic cardiovascular disease (ASCVD). The treatments often manage symptoms rather than getting at the root cause. It's a bit like putting a bandage on a leaky pipe instead of fixing the valve. Prof. Eva van Rooij, PhD, the company's co-founder and CEO, put it plainly. She said the next generation of medicines must address the underlying biology to create real, long-term solutions. Their mission? To translate the complex science of class IIa HDAC inhibition into actual therapies that can help patients and improve the entire healthcare system. ### A Precision Approach to a Complex Problem So what's their big idea? Revier is pioneering the first therapeutic approach that selectively targets class IIa histone deacetylases (HDACs) for cardiometabolic diseases. In simpler terms, HDACs are enzymes involved in many serious diseases. Earlier HDAC inhibitors were like using a sledgehammer—they hit multiple targets and caused nasty side effects. Revier's orally available small molecules are designed to be more like a scalpel. They aim to inhibit only the disease-driving activity while leaving healthy functions alone. Prof. Johannes Backs, MD, the scientific founder, explained that this precision could mean effective treatment without the dose-limiting problems of the past. Here's a quick breakdown of their strategy: - Selective targeting of class IIa HDACs only - Preservation of essential biological functions - Avoidance of side effects from inhibiting other HDAC classes - Focus on oral medications for better patient compliance ### Why Investors Are Betting on This Science The investor confidence isn't just about the science—it's about the team and the potential impact. Michael Hamacher, PhD, from KHAN Technology Transfer Fund II, called Revier's strategy a way to "unlock the therapeutic promise of HDAC biology." He highlighted the chance to reshape the standard of care for HFpEF, ASCVD, and related disorders. Daniel Stern, founder of Revier Invest Heidelberg, helped pull together regional stakeholders who see this as more than just an investment. It's about building a biotech hub and advancing medicine that could change lives. ### What's Next for Revier Therapeutics With the $6.4 million in hand, the company has a clear path forward. The capital will fuel the development of their preclinical pipeline, starting with their lead program for HFpEF and a second program for ASCVD. They're also building out their operational, scientific, and clinical teams to move from the lab toward human trials. It's a classic startup story with a high-stakes twist—translating deep scientific expertise into tangible therapies for conditions affecting millions. For professionals watching the European startup scene, especially in life sciences, Revier represents the kind of targeted, scientifically rigorous venture that could yield significant returns, both financially and for public health. Their progress will be one to watch as they work to turn precise molecular understanding into the next generation of heart disease treatments.